Abstract
Multiple authors observed superspreading aboard airplanes with high passenger density was less frequent than expected. This is possibly due to rapid air filtration on airplanes inflight reported by CDC as 20-30 air changes per hour (ACH). Filters may degrade over time with particle loading, but testing ACH typically involves generating aerosol contaminants (e.g. salt water, smoke, tracers) which may be unsafe or disallowed e.g. in occupied rooms or passenger aircraft. Herein we report the first verification, to our knowledge in the open literature, of ACH aboard commercial airliners while in flight by using a novel test procedure at the most penetrating particle size (MPPS) of 0.3□μm. Procedure uses handheld, 7-channel optical particle counter (HOPC) to track decay of ambient aerosols at MPPS, validated in a room and house. ACH of 0.6 was measured for surface deposition in an unventilated room, and 3 to 17 ACH with low-noise HEPA purifiers at high speed and Do-It-Yourself (DIY) purifiers at low speed (for reduced noise generation) consistent with their CADR based on volume of room and house. Aboard an Airbus A319, A321 and a Boeing 737-Max8/9, HOPC recorded (1) a burst of ambient aerosols when starting from rest on runway suggesting pollution from thrusting engines enters cabin (2) 11-12 ACH at MPPS after liftoff (3) transient aerosol fluctuations. Air filtration may not stop spread of SARS-Cov-2 at near-field (e.g. talking close by), but can potentially emulate far-field equivalent of N95 with 95% reduction of MPPS particles (20x) in a well-mixed room. Using 0.6 ACH baseline for unventilated rooms, at least 12 ACH at MPPS is required for far-field protection equivalent to N95 (95%). These results offer independent, experimentally-derived interpretations of 12 ACH recommended for airborne infection isolation rooms by CDC and WHO.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
sri{at}patientknowhow.com, www.patientknowhow.com
New ACH measurements added: -- Airbus A321 -- Boeing 737-Max8/9 -- Taotronics TT-AP0003
Data Availability
All data produced in the present study are available upon reasonable request to the authors